Repeat Ivermectin Mass Drug Administrations for MALaria Control II
Status:
Active, not recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
RIMDAMAL II is a double-blind, cluster randomized trial in Burkina Faso designed to test
whether repeated ivermectin mass drug administrations, integrated into a monthly delivery
platform with standard malaria control measures of seasonal malaria chemoprevention and
insecticide-treated bed net distribution in the Sahel, will reduce childhood malaria
incidence.
Phase:
Phase 3
Details
Lead Sponsor:
Brian Foy
Collaborators:
Institut de Recherche en Sciences de la Sante PATH Radboud University Yale University